## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 14.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($23.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance**
- Source: BioSpace | 20251217T113137 | Somewhat-Bullish | Relevance: 100%
- Pfizer (NYSE:PFE) has reaffirmed its full-year 2025 Adjusted Diluted EPS guidance and adjusted its 2025 revenue guidance to approximately $62.0 billion. The company also announced its full-year 2026 guidance, projecting revenues between $59.5 to $62.5 billion and Adjusted Diluted EPS in the range of $2.80 to $3.00, reflecting continued strategic investments in its pipeline and acquired assets despite anticipated declines from COVID-19 product sales and loss of exclusivity for certain products.

**2. Pfizer's Oncology and Obesity Pipelines Support a Narrow Moat Despite Looming Patent Expirations**
- Source: Morningstar | 20251217T050844 | Somewhat-Bullish | Relevance: 100%
- Pfizer's strong oncology and obesity drug pipelines are expected to help the company maintain a narrow economic moat, despite facing upcoming patent expirations. The company's large scale and diversified portfolio of patent-protected drugs continue to underpin its business strategy. Recent divestments of its off-patent and consumer businesses aim to refocus Pfizer on its innovative drug development.

**3. Shorepoint Capital Partners LLC Invests $3.06 Million in Pfizer Inc. $PFE**
- Source: MarketBeat | 20251216T120904 | Somewhat-Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC has initiated a new position in Pfizer Inc. (NYSE:PFE), acquiring 120,211 shares valued at approximately $3.06 million in the third quarter. Other institutional investors like Vanguard, Geode Capital Management, Norges Bank, Northern Trust Corp, and Amundi also significantly adjusted their holdings, bringing total institutional ownership to about 68.36%. Pfizer, with a market cap of around $150.4 billion, recently announced a quarterly dividend of $0.43 per share, yielding approximately 6.5%.

**4. Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251215T230857 | Neutral | Relevance: 100%
- Pfizer Inc. (NYSE: PFE) saw its stock close up 2.24% on Monday, December 15, 2025, but traded slightly lower after hours as anticipation builds for Tuesday morning's analyst call where 2026 financial guidance is expected. Key drivers for Monday's activity included a new autoimmune research partnership worth up to $890 million and news that the FDA has no current plans for a "black box" warning on COVID-19 vaccines. Investors are now focused on how Pfizer's guidance compares to analyst expectations and its plans for pipeline execution to counter future exclusivity headwinds.

**5. Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025**
- Source: ts2.tech | 20251215T190839 | Neutral | Relevance: 100%
- Pfizer (NYSE: PFE) is under investor scrutiny on December 15, 2025, driven by a new collaboration with Adaptive Biotechnologies, a crucial 2026 guidance event set for December 16, and ongoing debates about its pipeline and value. The stock is trading around $26.36, near its 52-week high, with analysts maintaining a "Hold" stance and a significant 6.5% dividend yield attracting income-focused investors. The upcoming guidance call is expected to provide clarity on cost cuts, post-COVID revenue, and the integration of new obesity-focused deals.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Morgan Stanley | $27 | $28 | -4% |
| 2025-12-15 | B of A Securiti | $28 | $29 | -3% |
| 2025-12-12 | Morgan Stanley | $28 | $32 | -12% |
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-15 | B of A Securiti | main | Neutral |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 14.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 14.22 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment negative (3 target cuts vs 1 raises). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $142.4B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 14.22 |
| Forward P/E | 8.3 |
| Current P/E | 8.0 |
| YoY Growth | -3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 0.2% (minimal 5-day change). Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.23% (CS: 30) | Neutral |
| RSI_14 | 45.9 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.022x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.07
- **Stop Loss:** $23.79 (5.1% risk)
- **Target:** $26.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 843
- **Position Value:** $21,134.01
- **Portfolio %:** 21.13%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*